Qualcomm has gone to reveal the finalists of its XPrize competition as the two are seeking to create a tricorder-like mobile diagnostic device.
A San Diego, California-based company, Qualcomm is a multinational enterprise. It targets the telecommunications equipment and semiconductor area. As such, it markets and produces wireless telecommunication services and products.
Qualcomm was the initiator of a somewhat unique contest. In its full name, the Qualcomm Tricorder X Prize is a prize contest. The inducement first place prize will offer a US $6 million Grand Prize.
First and Second Runner-Ups will also receive a $2 million respectively a $1 million prize.
The contest target may seem somewhat futuristic. It targets the development of a non-invasive, automatic health diagnostic tool. This will have to be contained in a sole portable device. It will also have to weigh a maximum of 5 pounds.
Such a device should be able to diagnose more than a dozen medical conditions. These include the likes of anemia, diabetes, pneumonia, atrial fibrillation, sleep apnea, and urinary tract infections.
As the aforementioned affections are among the mandatory diagnosis, the team can choose three optional ones. This will include issues such as hypertension, shingles, HIV, or melanoma.
A part of the XPrize competition name comes from the popular Star Trek. The science fiction TV series was the first to introduce a tricorder or an instant ailment diagnoses device.
The competition’s official website announced that the award will most likely be given out sometime in early 2017. For the moment, though, the XPrize competition announced its finalists.
As there have been quite a number of developers over its 4 years of existence, only the following two have remained.
Dynamic Biomarkers Group and Frontier Medical Devices have been named the XPrize competition finalists. Prize authorities also announced that their respective device consumer testing are currently underway.
Final Frontier Medical Devices is a Paoli, Pennsylvania-based group. It is led by the Harris brothers, who also founded the Basil Leaf Technologies.
The Dynamical Biomarkers Group is based in Zhongli City, Taiwan. It is led by Chung-Kang Peng, a Harvard Medical School Professor. Amongst its members, it includes scientists, engineers, and physicians. HTC, the mobile technology company, is also part of the team.
Grant Campany, one of the XPrize competition organizers released a statement. According to him, the two group have reached quite a feat.
The fact alone that they have reached the consumer testing stage can be considered an achievement on its own.
Campari also pointed out that this late stage in the competition is a very beneficial one. For one, it will help bring a sci-fi based vision closer to reality. But more importantly, it may be a step forward in medicine.
It could help global consumers beneficiate from a very user-friendly device. This device would be able to help them manage their own health in a proactive manner.
XPrize competition device testing is carried out at the UC San Diego. More exactly, at the Altman Translational Research Institute. Testing will continue to be carried out until early next year.
After being trained to use the device, which will be assisted by a clinical coordinator, the consumers will be left to carry out an independent, 90-minutes long session.
Image Source: Flickr